CXCR4 and neoplasm: The MDA-MB-231 tumor-bearing mice were randomly divided into four groups, which were treated by PBS only, anti-CXCR4-peptide, Try-NaGdF4 NDs and anti-CXCR4-NaGdF4 NDs, respectively.